EGFR's Poor Sibling
Mené sur 74 patients atteints d'un cancer du poumon non à petites cellules HER2+ de stade avancé ou métastatique, cet essai de phase IA/IB évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du zongertinib (un inhibiteur de tyrosine kinase ciblant HER2)
The discovery that many lung cancers are driven by a single dominant constitutively activated “driver” oncogene represented a quantum leap in the therapy of lung cancer. Potent small molecules were developed that could turn off these genes, with dramatic clinical therapeutic efficacy. Before their discovery, cancer therapeutics were identified by chance observations or random screening of naturally derived toxic compounds in the search for a perceptible therapeutic index. These therapies were often toxic and minimally effective and in the late 1990s improved the median survival for metastatic lung cancer only marginally, from approximately 6 to 8 months to approximately (...)
New England Journal of Medicine , éditorial, 2026